609 related articles for article (PubMed ID: 25547501)
21. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.
Shouval R; Labopin M; Bomze D; Baerlocher GM; Capria S; Blaise D; Hänel M; Forcade E; Huynh A; Saccardi R; Milone G; Zuckerman T; Reményi P; Versluis J; Esteve J; Gorin NC; Mohty M; Nagler A
Bone Marrow Transplant; 2020 Dec; 55(12):2244-2253. PubMed ID: 32388535
[TBL] [Abstract][Full Text] [Related]
22. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
[TBL] [Abstract][Full Text] [Related]
23. Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia.
Rodríguez-Macías G; Martínez-Laperche C; Gayoso J; Noriega V; Serrano D; Balsalobre P; Muñoz-Martínez C; Díez-Martín JL; Buño I
Hum Pathol; 2013 Aug; 44(8):1696-9. PubMed ID: 23465275
[TBL] [Abstract][Full Text] [Related]
24. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
27. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years.
Zhang Y; Zhang Y; Chen Q; Tang G; Zhang W; Yang J; Wang J; Hu X
Ann Hematol; 2019 Apr; 98(4):997-1007. PubMed ID: 30607578
[TBL] [Abstract][Full Text] [Related]
29. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H
Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325
[TBL] [Abstract][Full Text] [Related]
30. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
31. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.
Nakai K; Kanda Y; Fukuhara S; Sakamaki H; Okamoto S; Kodera Y; Tanosaki R; Takahashi S; Matsushima T; Atsuta Y; Hamajima N; Kasai M; Kato S
Leukemia; 2005 Mar; 19(3):396-401. PubMed ID: 15674354
[TBL] [Abstract][Full Text] [Related]
32. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
34. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158
[TBL] [Abstract][Full Text] [Related]
35. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.
Schetelig J; Schaich M; Schäfer-Eckart K; Hänel M; Aulitzky WE; Einsele H; Schmitz N; Rösler W; Stelljes M; Baldus CD; Ho AD; Neubauer A; Serve H; Mayer J; Berdel WE; Mohr B; Oelschlägel U; Parmentier S; Röllig C; Kramer M; Platzbecker U; Illmer T; Thiede C; Bornhäuser M; Ehninger G;
Leukemia; 2015 May; 29(5):1060-8. PubMed ID: 25434303
[TBL] [Abstract][Full Text] [Related]
37. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
38. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.
Imahashi N; Suzuki R; Fukuda T; Kakihana K; Kanamori H; Eto T; Mori T; Kobayashi N; Iwato K; Sakura T; Ikegame K; Kurokawa M; Kondo T; Iida H; Sakamaki H; Tanaka J; Kawa K; Morishima Y; Atsuta Y; Miyamura K
Bone Marrow Transplant; 2013 Jan; 48(1):56-62. PubMed ID: 22705800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
